Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Supernus Launches Oxtellar XR(TM) in the United States



Supernus Launches Oxtellar XR(TM) in the United States

ROCKVILLE, Md., Feb. 1, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals,
Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced that
Oxtellar XR tablets are now available for sale in the US. Oxtellar XR is a
novel once-daily extended release antiepileptic drug indicated for adjunctive
therapy in the treatment of partial seizures in adults and in children 6 to 17
years of age. The product has been shipped to major wholesalers in the market,
and the Company's sales force of approximately 75 sales representatives will
start promoting the product on February 4.

"The commercial launch of Oxtellar XR marks the achievement of our vision of
becoming a commercial organization marketing its own products in the CNS
specialty pharma sector. It also confirms the long standing heritage we have
in strong execution against our corporate goals said Jack Khattar, President &
CEO, of Supernus. I would like to thank all Supernus employees for their hard
work and dedication that allowed us to deliver on our commitment to providing
innovative therapeutic options to patients who suffer from epilepsy," added
Jack Khattar.

About Oxtellar XR

Oxtellar XR is a novel once-daily extended release formulation of
oxcarbazepine. It is an antiepileptic drug (AED) indicated for adjunctive
therapy in the treatment of partial seizures in adults and in children 6 to 17
years of age. The recommended daily dose for adults is 1200 mg to 2400 mg once
per day, and for children 6 to 17 years of age is 900 mg to 1800 mg depending
on weight. The product is available in 150 mg, 300 mg and 600 mg
extended-release tablets.

For full prescribing and safety information, click here.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on developing and commercializing products for the treatment of central
nervous system, or CNS, diseases. The Company has one marketed product for
epilepsy, Oxtellar XR (extended-release oxcarbazepine), and one tentatively
approved product for epilepsy, Trokendi XR™ (extended-release topiramate). The
Company is also developing several product candidates in psychiatry to address
large market opportunities in ADHD, including ADHD patients with impulsive
aggression. These product candidates include SPN-810 for impulsive aggression
in ADHD and SPN-812 for ADHD.

Forward-Looking Statements:

This press release includes forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These statements do not
convey historical information, but relate to predicted or potential future
events that are based upon management's current expectations. These statements
are subject to risks and uncertainties that could cause actual results to
differ materially from those expressed or implied by such statements. In
addition to the factors mentioned in this press release, such risks and
uncertainties include, but are not limited to, the Company's ability to raise
sufficient capital to implement its corporate strategy; the implementation of
the Company's corporate strategy; the Company's future financial performance
and projected expenditures; the Company's product research and development
activities, including the timing and progress of the Company's clinical
trials, and projected expenditures; the Company's ability to receive, and the
timing of any receipt of, regulatory approvals to develop and commercialize
the Company's product candidates; the Company's ability to protect its
intellectual property and operate its business without infringing upon the
intellectual property rights of others; the Company's expectations regarding
federal, state and foreign regulatory requirements; the therapeutic benefits,
effectiveness and safety of the Company's products and product candidates; the
accuracy of the Company's estimates of the size and characteristics of the
markets that may be addressed by its products and product candidates; the
Company's ability to increase its manufacturing capabilities for its products
and product candidates; the Company's projected markets and growth in
markets;the Company's staffing needs; and other risk factors set forth from
time to time in the Company's periodic reports and other filings made with the
Securities and Exchange Commission. The Company undertakes no obligation to
update the information in this press release to reflect events or
circumstances after the date hereof or to reflect the occurrence of
anticipated or unanticipated events.

CONTACT: Jack Khattar, President & CEO
         Gregory S. Patrick, Vice President and CFO
         Supernus Pharmaceuticals, Inc.
         Tel: (301) 838-2591
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement